Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 311

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 311
---
 clinical trial subjects and employees, and patients, on our networks, and with our third-party
cloud service providers. The secure processing, maintenance and transmission of this information is critical to our operations. Despite
our security measures, our information technology and infrastructure, and that of our third parties, may be vulnerable to attacks by
hackers or breached due to employee error, malfeasance, or other disruptions. Any breach could compromise our networks and the information
stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure or other loss of information could result
in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, disrupt
our operations, damage our reputation, and cause a loss of confidence in our products and our ability to conduct clinical trials, which
could adversely affect our business and reputation and lead to delays in gaining regulatory approvals for Telomir-1 or other product
candidates.

Failure
of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt
the operation of our business.

Our
business is increasingly dependent on critical, complex, and interdependent information technology (“IT”) systems, including
internet-based systems, some of which are managed or hosted by third parties, to support business processes as well as internal and external
communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion,
and computer viruses, which may result in the impairment of our ability to operate our business effectively.

We
are continuously evaluating and, where appropriate, enhancing our IT systems to address our planned growth, including to support our
planned manufacturing operations. There are inherent costs and risks associated with implementing the enhancements to our IT systems,
including potential delays in access to, or errors in, critical business and financial information, substantial capital expenditures,
additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced
systems, demands on management time, and costs of delays or difficulties in transitioning to the enhanced systems, any of which could
harm our business and results of operations. In addition, the implementation of enhancements to our IT systems may not result in productivity
improvements to a level that outweighs the costs of implementation, or at all. In addition, our systems and the systems of our third-party
providers and collaborators are potentially vulnerable to data security breaches which may expose sensitive data to unauthorized persons
or to the public. Such data security breaches could lead to the